Название продукции:3-Bromo-2-chloro-6-methyl-5-nitropyridine
IUPAC Name:3-bromo-2-chloro-6-methyl-5-nitropyridine
- CAS：856834-95-2
- Молекулярная формула：C6H4BrClN2O2
- Чистота：98%
- Номер в каталоге：CM176105
- Молекулярная масса：251.46
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:856834-95-2
- Молекулярная формула:C6H4BrClN2O2
- Точка плавления:-
- Smiles-код:O=[N+](C1=C(C)N=C(Cl)C(Br)=C1)[O-]
- Плотность:
- Номер в каталоге:CM176105
- Молекулярная масса:251.46
- Точка кипения:296°C at 760 mmHg
- Номер Mdl:MFCD09839270
- Хранение:Keep in inert atmosphere, store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Lunresertib Camonsertib
- Repare Therapeutics announces Fast Track Designation granted by the FDA for Lunresertib in combination with Camonsertib for the treatment of platinum-resistant ovarian cancer. Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1 (PKMYT1) is a regulator of CDK1 phosphorylation, and PKMYT1 is identified as synthetic lethal with cyclin E1 (CCNE1) amplification.
Lunresertib (RP-6306) is a first-in-class PKMYT1 inhibitor to enter clinical trial. Lunresertib is studied alone and in combination with Camonsertib in patients with advanced solid tumors. Camonsertib (RP-3500) is a potent and selective ATR inhibitor, that helps Lunresertib activate CDK1 and promotes premature mitosis. The combination is previously granted Fast Track Designation for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated endometrial cancer.
Поиск 
+86 21 5895 0110 
